When investors think of biotech stocks, they tend to focus on the “lotto tickets.” That is, start-ups betting their entire existence on a single new drug or compound. Well, that ideology could not be further from the truth for our newest Best Healthcare Stocks Dividend List recommendation. With a massive portfolio of blockbuster drugs, our pick mints cash and has rewarded investors with growing dividends for a decade!
As one of the first biotech pioneers, our pick was able to turn its early wins into a variety of successes. Now our pick is a leading oncology and blood disease specialist. Moreover, our pick has continued to benefit from its moves into biosimilars – generic versions of branded biotech drugs, helping to keep cash flowing while it works on its own pipeline and patent portfolio.
And with a series of big buyouts, partnerships and other joint ventures, our pick features a long runway for potential growth and future blockbuster drugs.
In the end, our pick continues to prove that biotech is not just about “lotto tickets” and that there is plenty of dividend growth to be had.
In addition to our new biotech pick, we’ve also increased our positions in two other pharmaceuticals as well as sold a medical device maker and reduced our position in another biotech stock.
You can check out the Best Healthcare Dividend Stocks List to explore all the stocks.
